Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation

Journal of Inherited Metabolic Disease

Volumn 30, Issue 3, 2007, Pages 388-399

  Fisher, N M ^a   Meksawan, K ^c   Limprasertkul, A ^a   Isackson, P J ^b   Pendergast, D R ^b   Vladutiu, G D ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESTYRAMINE; EZETIMIBE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LACTIC ACID; LIPOPROTEIN; OXYGEN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTHRALGIA; ARTICLE; BODY FAT; BODY HEIGHT; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXERCISE; FAT INTAKE; FEMALE; GENETIC DISORDER; GROUPS BY AGE; HUMAN; LEUKOCYTE; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; LUNG GAS EXCHANGE; MALE; MOLECULAR GENETICS; MUSCLE STIFFNESS; MUSCLE TWITCH; MYALGIA; MYOPATHY; OXIDATION REDUCTION REACTION; OXYGEN CONSUMPTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; WEAKNESS;

ADIPOSE TISSUE; ADULT; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; ENERGY INTAKE; EXERCISE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KNEE JOINT; LEUKOCYTES; LIPID METABOLISM, INBORN ERRORS; LIPIDS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NUTRITION ASSESSMENT; OXIDATION-REDUCTION; OXYGEN CONSUMPTION;

EID: 34250011126     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-007-0449-6     Document Type: Article

References (32)

1. Anonymous (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
2. Castano G, Mas R, Arruzazabala ML, et al (1999) Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemia patients. Int J Clin Pharm Res 19: 105-116.
3. Champe PC, Harvey RA, Ferrier DR (2005) Biochemistry, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 179-198.
4. Dipietro L, Caspersen CJ, Ostfeld AM, Nadel ER (1993) A survey for assessing physical activity among older adults. Med Sci Sports Exerc 25: 628-242.
5. Duane WC (1994) Effects of lovastatin and dietary cholesterol on bile acid kinetics and bile lipid composition in healthy male subjects. J Lipid Res 35: 501-509.
6. Fisher NM, Pendergast DR, Calkins E (1990) Maximal isometric torque of knee extension as a function of muscle length in subjects of advancing age. Arch Phys Med Rehabil 71 (10): 729-734.
7. Foley KA, Massing MW, Simpson RJ Jr, Alexander CM, Markson LE (2004) Population implications of changes in lipid management in patients with coronary heart disease. Am J Cardiol 93: 193-195.
8. Head A, Jakeman PM, Kendall MJ, Cramb R, Maxwell S (1993) The impact of a short course of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers. Postgrad Med J 69 (809): 197-203.
9. Hoppeler H, Billeter R, Horvath PJ, Leddy JJ, Pendergast DR (1999) Muscle structure with low and high fat diets in well trained male runners. Int J Sports Med 20 (8): 522-526.
10. Horvath PJ, Eagen C, Fisher NM, Leddy JJ, Pendergast DR (2000) The effects of varying dietary fat on performance and metabolism in trained male and female runners. J Am Coll Nutr 19 (1): 52-60.
11. Iliadis EA, Rosenson RS (1999) Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 22: 25-28.
12. Lofberg M, Jankala H, Paetau A, Harkonen M, Somer H (1998) Metabolic causes of recurrent rhabdomyolysis. Acta Neurol Scand 98: 268-275.
13. Langer T, Levy RI (1968) Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 279: 856-858.
14. Meksawan K, Pendergast DR, Vladutiu GD, Awad A (2005) Effect of dietary fat intake on total body and white blood cell fat oxidation in exercised sedentary subjects. Nutr Res 25: 225-237.
15. O'Meara JG, Kardia SLR, Armon JL, Brown CA, Boerwinkle E, Tumer ST (2004) Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 164: 1313-1318.
16. Paolisso G, Barbagallo M, Peterella G, et al (2000) Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent patients. Atherosclerosis 150: 121-127.
17. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lefant C (2002) ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 40: 567-572.
18. Pendergast DR, Fisher NM, Meksawan K, Doubrava M, Vladutiu GD (2004) The distribution of white blood cell fat oxidation in health and disease. J Inherit Metab Dis 27: 1-11.
19. Phillips PS, Haas RH, Barshop B, et al (2002) Utility of abnormal 3-methylglutaconic aciduria (3MGA) in diagnosing statin associated myopathy. Atheroscler Thromb Vasc Biol Online J 22: 878.
20. Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH (2004) Statin myotoxicity is associated with changes in cardiopulmonary function. Atherosclerosis 177: 183-188.
21. Qureshi AA, Peterson DM (2001) The combined efffcts of novel tocotrienols and lovastatin on lipid metabolism in chickens Atherosclerosis 156: 39-47.
22. Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116: 408-416.
23. Rustemeijer C, Schouten JA, Janssens EN, Spooren PF, van Doormaal JJ (1997) Pravastatin in diabetes-associated hypercholesterolemia. Acta Diabetol 34: 294-300.
24. Scharnagl H, Schinker R, Gierens H, Nauck M, Wieland H, Marz W (2001) Effect of atorvasatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol 62: 1545-1555.
25. Schrauwen P, Hoppeler H, Billeter R, Bakker A, Pendergast DR (2001) Fiber type dependent upregulation of human skeletal muscle UCP2 and UPC3 mRNA expression by high-fat diet. Int J Obes 25: 449-456.
26. Seargeant LE, Balachandra K, Mallory C, Dilling LA, Greenburg CR (1999) A simple screening test for fatty acid oxidation defects using whole-blood palmitate oxidation. J Inherit Metab Dis 22: 740-746.
27. Smith JL, Roach PD, Wittenberg LN, et al (2000) Effect of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 15: 871-879.
28. Staels B, van Tol A, Fruchart JC, Auwerx J (1996) Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat Israel J Med Sci 32: 490-498.
29. Teo KK, Burton JR, Buller CE, et al (2000) Long-term effects of cholesterol lowering and angiotensin-converting enzymes inhibition on coronary atherosclerosis: The Simvastating/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 102: 1748-1754.
30. Vladutiu GD, Bennett MJ, Fisher NM, Small DS, Leddy JJ, Pendergast DR (2002) Phenotypic variability among first-degree relatives with the same mutations in the carnitine palmitoyltransferase II gene. Muscle Nerve 26 (4): 492-498.
31. Wilmore JH, Costill DL (2004) Physiology of Sport and Exercise, 3rd. edn. Champaign, IL: Human Kinetics, 118-139, 184-186.
32. Zambon D, Ros E, Rodriguez-Villar C, et al (1999) Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidema: Additive effects of combination treatment on lipid regulation. Metabolism 48: 47-54.